Successful treatment of recurrent focal segmental glomerulosclerosis with a low dose rituximab in a kidney transplant recipient

Renal Failure

Volumn 36, Issue 4, 2014, Pages 623-626

  Cho, Jang Hee ^a,b   Lee, Jong Hak ^a,b   Park, Ga Young ^a,b   Lim, Jeong Hoon ^a,b   Kim, Jun Seop ^a,b   Kang, Yoon Jung ^a,b   Kwon, Owen ^a,b   Choi, Ji Young ^a,b   Park, Sun Hee ^a,b   Kim, Yong Lim ^a,b   Kim, Hyung Kee ^a   Huh, Seung ^a   Kim, Chan Duck ^a,b  

^a Kyungpook National University School of Medicine   (South Korea)

^b Clinical Research Center for End Stage Renal Disease   (South Korea)

Author keywords

Focal segmental glomerulosclerosis; Kidney transplantation; Plasmapheresis; Relapse; Rituximab

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID; PREDNISOLONE; RITUXIMAB; TACROLIMUS; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; FOCAL GLOMERULOSCLEROSIS; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMODIALYSIS; HUMAN; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; OLIGURIA; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEINURIA; RELAPSE; REMISSION; STEROID THERAPY; TREATMENT OUTCOME; BLOOD; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; RECURRENT DISEASE; URINE;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CREATININE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY TRANSPLANTATION; MALE; PLASMAPHERESIS; PROTEINURIA; RECURRENCE; TRANSPLANT RECIPIENTS;

EID: 84899032356     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2014.882238     Document Type: Article

References (21)

1. Gipson DS, Gibson K, Gipson PE, Watkins S, Moxey-Mims M. Therapeutic approach to FSGS in children. Pediatr Nephrol. 2006; 22(1):28-36
2. Kitiyakara C, Eggers P, Kopp JB. Twenty-one-year trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004;44(5):815-825
3. Floege J. Recurrent glomerulonephritis following renal transplantation: an update. Nephrol Dial Transplant. 2003;18(7):1260-1265
4. Newstead CG. Recurrent disease in renal transplants. Nephrol Dial Transplant. 2003;18(90006):68vi-74vi.
5. Nakayama M, Kamei K, Nozu K, et al. Rituximab for refractory focal segmental glomerulosclerosis. Pediatr Nephrol. 2007; 23(3):481-485
6. Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve nephrotic syndrome in renal transplant patients with recurrent focal segmental glomerulosclerosis. Am J Transplant. 2008;8(1):222-227
7. Rodrguez-Ferrero M, Ampuero J, Anaya F. Rituximab and chronic plasmapheresis therapy of nephrotic syndrome in renal transplantation patients with recurrent focal segmental glomerulosclerosis. Transplant Proc. 2009;41(6):2406-2408
8. Strologo LD, Guzzo I, Laurenzi C, et al. Use of rituximab in focal glomerulosclerosis relapses after renal transplantation. Transplantation. 2009;88(3):417-420
9. Bayrakci US, Baskin E, Sakalli H, Karakayali H, Haberal M. Rituximab for post-transplant recurrences of FSGS. Pediatr Transplant. 2009;13(2):240-243
10. Stewart ZA, Shetty R, Nair R, Reed AI, Brophy PD. Case report: successful treatment of recurrent focal segmental glomerulosclerosis with a novel rituximab regimen. Transplant Proc. 2011; 43(10):3994-3996
11. Audard V, Kamar N, Sahali D, et al. Rituximab therapy prevents focal and segmental glomerulosclerosis recurrence after a second renal transplantation. Transplant Int. 2012;25(5):e62-e66
12. Meyer TN, Thaiss F, Stahl RA. Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transplant Int. 2007; 20(12):1066-1071
13. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med. 2006;354(18):1961-1963
14. Evens AM, Roy R, Sterrenberg D, Moll MZ, Chadburn A, Gordon LI. Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy. Curr Oncol Rep. 2010;12(6):383-394
15. Toki D, Ishida H, Horita S, Setoguchi K, Yamaguchi Y, Tanabe K. Impact of low-dose rituximab on splenic B cells in ABOincompatible renal transplant recipients. Transplant Int. 2009; 22(4):447-454
16. Genberg H, Hansson A, Wernerson A, Wennberg L, Tyden G. Pharmacodynamics of rituximab in kidney transplantation. Transplantation. 2007;84(12 Suppl):S33-S36
17. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006; 6(5 Pt 1):859-866
18. Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011; 17(8):952-960
19. Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood. 2006;107(3):1070-1077
20. Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85ra46
21. Gallon L, Leventhal J, Skaro A, Kanwar Y, Alvarado A. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med. 2012;366(17):1648-1649.